[ad_1]
Jakarta, CNBC Indonesia – After obtaining clearance from the United States Food and Drug Administration (BPOM) or the US FFood and Drug Administration (FDA), a corona virus vaccine manufactured by Moderna Inc, an issuer traded on the Nasdaq Exchange under the code MRNA, ready to be distributed.
This can be seen in employees at a Memphis-area factory preparing a vaccine developed by Moderna and the National Institutes of Health, according to an AP News report, quoted on Sunday (12/20/2020).
Workers are seen starting to pack the shipment of the Covid-19 vaccine, which is needed to control the corona virus pandemic in the US.
Not only Moderna, formerly the FDA, also announced the emergency use of the Pfizer-BioNTech vaccine on Saturday. With the availability of these two vaccines, mass vaccination in the US can begin.
“With two vaccines now available for the prevention of Covid-19, the FDA has taken another important step in the fight against the global pandemic that causes massive hospitalizations and deaths in the United States every day,” said the FDA commissioner, Stephen M. Hahn, MD, “quoted by Antara. Reuters, quoted on Sunday (12/20/2020).
At least six million doses of the vaccine will be shipped throughout the United States next week. The FDA’s decision received a warm welcome from US President Donald Trump. The man who is about to resign in January 2021 tweeted “Congratulations, the Modern vaccine is now available” on his Twitter account @realDonadTrump.
The United States was the first country to grant Moderna permission. Meanwhile, Pfizer, the United States, became the second country after Great Britain, which issued a permit on December 2.
Moderna is a pharmaceutical company based in Massachusetts, USA The effectiveness of this vaccine according to research is approximately 95% compared to placebo.
Earlier on Thursday, an independent FDA advisory panel supported the use of the Moderna vaccine. All panel members voted in their entirety that the benefits of vaccines outweigh the risks for citizens 18 and older, but one vote abstained from the meeting.
This good news did not strengthen MRNA’s shares on the Nasdaq. At the close of operations last Friday (12/18), MRNA’s shares were at minus 2.62% at the level of US $ 140.23 / share. However, so far this year, MRNA’s shares have soared 617%.
[Gambas:Video CNBC]
(bag of bag)
[ad_2]
